Shanghai Ruijin Hospital’s Hainan subsidiary has initiated a real-world study for Orserdu (elacestrant), a next-generation selective estrogen receptor degrader (SERD) originally developed by Eisai (TYO: 4523). The drug was transferred to Radius Health for global development back in 2006. In a strategic move in July 2020, the Menarini Group, based in Italy, secured an exclusive licensing deal with Radius Health, acquiring the global commercialization rights to Orserdu.
Orserdu received approvals in the U.S. and Europe in January and September of the previous year, respectively, for the treatment of ER+, HER2- advanced or metastatic breast cancer (mBC) with ESR1 mutation. Following this, China’s SciClone Pharmaceuticals Inc. (6600.HK) entered into a licensing and cooperation agreement with the Menarini Group in November 2023, thereby obtaining exclusive rights to develop and commercialize the drug in China.- Flcube.com
